AZD-0466

N/A

Report date: 2025/01/08 20:00:42
NME

Base Information

Drug NameAZD-0466
Drug Alias NameAZD-0466
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator Bcl-X inhibitorsApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-XApoptosis regulator Bcl-2
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPortugalItaly +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic NeoplasmsMultiple Myeloma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A